Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors | Zendy

Tommaso Simoncini | Zendy; X-D. Fu | Zendy; Antonio Caruso | Zendy; Silvia Garibaldi | Zendy; Chiara Baldacci | Zendy; Maria Silvia Giretti | Zendy; Paolo Mannella | Zendy; Marina Inés Flamini | Zendy; Angel Matías Sanchez | Zendy; Andrea R. Genazzani | Zendy

Open Access

Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors

Author(s) -

Tommaso Simoncini,

X-D. Fu,

Antonio Caruso,

Silvia Garibaldi,

Chiara Baldacci,

Maria Silvia Giretti,

Paolo Mannella,

Marina Inés Flamini,

Angel Matías Sanchez,

Andrea R. Genazzani

Publication year - 2007

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dem109

Subject(s) - endocrinology , mineralocorticoid receptor , medicine , drospirenone , enos , mineralocorticoid , aldosterone , progestin , nitric oxide , receptor , nitric oxide synthase type iii , eplerenone , chemistry , nitric oxide synthase , hormone

Progestins have actions on the cardiovascular system, which depend on the structure as well as on receptor binding characteristics. Drospirenone (DRSP) is a progestin that uniquely interferes with the signaling of the mineralocorticoid receptor (MR). Hormone therapy containing DRSP results in blood pressure reduction in hypertensive post-menopausal women.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research